CPA
NBIX icon

Capital Performance Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Capital Performance Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,093
Closed -$407K – 435
2026
Q1 		$407K Buy
3,093
+457
+17% +$60.6K 0.03% 249
2025
Q4 		$374K Buy
2,636
+171
+7% +$24.8K 0.03% 267
2025
Q3 		$346K Buy
2,465
+862
+54% +$117K 0.06% 187
2025
Q2 		$201K Buy
+1,603
New +$184K 0.04% 252
2025
Q1 		– Sell
-1,730
Closed -$236K – 276
2024
Q4 		$236K Buy
1,730
+1,586
+1,101% +$196K 0.08% 129
2024
Q3 		$16.6K Buy
+144
New +$19.7K 0.01% 663

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Performance Advisors's NBIX Position: Q2 2026 in Review

Capital Performance Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 3,093 shares — an estimated $407K sold.

Capital Performance Advisors first reported a position in NBIX in Q3 2024 and held it in 6 quarters. The position peaked at $407K in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Capital Performance Advisors reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 3,093 Neurocrine Biosciences shares in Q2 2026, an estimated $407K.
  • Capital Performance Advisors first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 6 quarters.
  • Capital Performance Advisors's Neurocrine Biosciences position peaked at $407K in Q1 2026.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.